person · Reporting owner

Van Naarden Jacob

Disclosed activity across 2 companies

Tapewire entity: 11096
SEC CIK: 0001661254

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ELI LILLY & CoLLY · Entity 2794	EVP,Pres LLY Oncology&HdCorpBD	February 09, 2026	February 11, 2026
Loxo Oncology, Inc.LOXO · Entity 160155	Chief Operating Officer	February 15, 2019	February 15, 2019

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ELI LILLY & Co

Report date February 09, 2026 · Filed February 11, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	26,626.498	Reported balance After 2026-02-09 transaction · row 1 1 source row Row 1 · 2026-02-09 · Grant · Acquired 4,865.888 · Balance 26,626.498
Common StockSEC Table I · non-derivative	IndirectVan Naarden Family Trust	4,342	Reported balance Holding disclosure · report date 2026-02-09 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 4,342 F1: The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectBy SLAT	5,302	Reported balance Holding disclosure · report date 2026-02-09 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 5,302 F2: On February 5, 2026, the Reporting Person's spouse transferred 5,302 shares of Eli Lilly and Company common stock to a spousal lifetime access trust, of which the Reporting Person is the trustee and a beneficiary. The transfer included 1,000 spouse-held shares previously reported as directly held due to an administrative error. F1: The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

F2: On February 5, 2026, the Reporting Person's spouse transferred 5,302 shares of Eli Lilly and Company common stock to a spousal lifetime access trust, of which the Reporting Person is the trustee and a beneficiary. The transfer included 1,000 spouse-held shares previously reported as directly held due to an administrative error.

Loxo Oncology, Inc.

Report date February 15, 2019 · Filed February 15, 2019

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2019-02-15 transaction · row 1 1 source row Row 1 · 2019-02-15 · Disposition to issuer · Disposed 19,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.65 · Expires 2024-06-18	Direct	Reported balance After 2019-02-15 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2019-02-15 · Disposition to issuer · Disposed 35,026 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.67 · Expires 2024-12-18	Direct	Reported balance After 2019-02-15 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2019-02-15 · Disposition to issuer · Disposed 78,943 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.69 · Expires 2025-12-15	Direct	Reported balance After 2019-02-15 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2019-02-15 · Disposition to issuer · Disposed 43,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.27 · Expires 2026-12-05	Direct	Reported balance After 2019-02-15 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2019-02-15 · Disposition to issuer · Disposed 74,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.56 · Expires 2027-03-14	Direct	Reported balance After 2019-02-15 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2019-02-15 · Disposition to issuer · Disposed 35,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $84.88 · Expires 2028-01-03	Direct	Reported balance After 2019-02-15 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2019-02-15 · Disposition to issuer · Disposed 200,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $139.77 · Expires 2029-01-01	Direct	Reported balance After 2019-02-15 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2019-02-15 · Disposition to issuer · Disposed 57,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes.

F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
August 14, 2018 Filed Aug 15, 2018 17:27 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	4,500	$0.00 Strike: $3.65	$0.00	Disclosure SEC source: 0001567619-18-001208 · doc1.xml · derivative · entry 11 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,269 Underlying: Common Stock · 4,500 shares Expires 2024-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F10 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the shares subject to the option on May 12, 2015, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document
August 14, 2018 Filed Aug 15, 2018 17:27 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	701	$160.70	$112,650.49	Disclosure SEC source: 0001567619-18-001208 · doc1.xml · nonDerivative · entry 9 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,700 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F9 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $160.48 to $161.13 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
August 14, 2018 Filed Aug 15, 2018 17:27 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	3,199	$159.91	$511,542.49	Disclosure SEC source: 0001567619-18-001208 · doc1.xml · nonDerivative · entry 8 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,401 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F8 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $159.46 to $160.35 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
August 14, 2018 Filed Aug 15, 2018 17:27 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	600	$159.08	$95,449.20	Disclosure SEC source: 0001567619-18-001208 · doc1.xml · nonDerivative · entry 7 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,600 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F7 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $158.43 to $159.27 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
August 14, 2018 Filed Aug 15, 2018 17:27 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	Exercise / conversionCommon Stock	4,500	$3.65	$16,416.00	Disclosure SEC source: 0001567619-18-001208 · doc1.xml · nonDerivative · entry 6 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document
August 13, 2018 Filed Aug 15, 2018 17:27 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	5,500	$0.00 Strike: $3.65	$0.00	Disclosure SEC source: 0001567619-18-001208 · doc1.xml · derivative · entry 10 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,769 Underlying: Common Stock · 5,500 shares Expires 2024-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F10 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the shares subject to the option on May 12, 2015, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document
August 13, 2018 Filed Aug 15, 2018 17:27 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	200	$160.60	$32,119.00	Disclosure SEC source: 0001567619-18-001208 · doc1.xml · nonDerivative · entry 5 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,700 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F6 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $160.49 to $160.70 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
August 13, 2018 Filed Aug 15, 2018 17:27 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	1,500	$159.69	$239,533.95	Disclosure SEC source: 0001567619-18-001208 · doc1.xml · nonDerivative · entry 4 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,900 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $159.26 to $160.23 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
August 13, 2018 Filed Aug 15, 2018 17:27 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	3,070	$158.66	$487,092.03	Disclosure SEC source: 0001567619-18-001208 · doc1.xml · nonDerivative · entry 3 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,400 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $158.11 to $159.09 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
August 13, 2018 Filed Aug 15, 2018 17:27 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	730	$157.62	$115,059.32	Disclosure SEC source: 0001567619-18-001208 · doc1.xml · nonDerivative · entry 2 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,470 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $157.04 to $157.99 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
August 13, 2018 Filed Aug 15, 2018 17:27 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	Exercise / conversionCommon Stock	5,500	$3.65	$20,064.00	Disclosure SEC source: 0001567619-18-001208 · doc1.xml · nonDerivative · entry 1 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document
July 10, 2018 Filed Jul 11, 2018 17:03 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	Exercise / conversionEmployee Stock Option (right to buy) · Derivative	1,541	$0.00 Strike: $3.65	$0.00	Disclosure SEC source: 0001140361-18-032160 · doc1.xml · derivative · entry 15 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,269 Underlying: Common Stock · 1,541 shares Expires 2024-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F9 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the shares subject to the option on May 12, 2015, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document
July 10, 2018 Filed Jul 11, 2018 17:03 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	100	$183.19	$18,319.00	Disclosure SEC source: 0001140361-18-032160 · doc1.xml · nonDerivative · entry 13 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,700 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document
July 10, 2018 Filed Jul 11, 2018 17:03 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	100	$181.96	$18,196.00	Disclosure SEC source: 0001140361-18-032160 · doc1.xml · nonDerivative · entry 12 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,800 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document
July 10, 2018 Filed Jul 11, 2018 17:03 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	300	$180.95	$54,284.01	Disclosure SEC source: 0001140361-18-032160 · doc1.xml · nonDerivative · entry 11 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,900 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F8 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $180.54 to $181.15 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document
July 10, 2018 Filed Jul 11, 2018 17:03 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	361	$179.50	$64,799.72	Disclosure SEC source: 0001140361-18-032160 · doc1.xml · nonDerivative · entry 10 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,200 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F7 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $179.06 to $179.93 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document
July 10, 2018 Filed Jul 11, 2018 17:03 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	680	$178.39	$121,308.12	Disclosure SEC source: 0001140361-18-032160 · doc1.xml · nonDerivative · entry 9 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,561 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F6 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $177.91 to $178.74 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document
July 10, 2018 Filed Jul 11, 2018 17:03 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	Exercise / conversionCommon Stock	1,541	$3.65	$5,621.57	Disclosure SEC source: 0001140361-18-032160 · doc1.xml · nonDerivative · entry 8 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,241 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document
July 09, 2018 Filed Jul 11, 2018 17:03 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	Exercise / conversionEmployee Stock Option (right to buy) · Derivative	1,541	$0.00 Strike: $3.65	$0.00	Disclosure SEC source: 0001140361-18-032160 · doc1.xml · derivative · entry 14 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,810 Underlying: Common Stock · 1,541 shares Expires 2024-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F9 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the shares subject to the option on May 12, 2015, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document
July 09, 2018 Filed Jul 11, 2018 17:03 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	100	$191.64	$19,164.00	Disclosure SEC source: 0001140361-18-032160 · doc1.xml · nonDerivative · entry 7 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,700 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document
July 09, 2018 Filed Jul 11, 2018 17:03 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	100	$189.12	$18,912.00	Disclosure SEC source: 0001140361-18-032160 · doc1.xml · nonDerivative · entry 6 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,800 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document
July 09, 2018 Filed Jul 11, 2018 17:03 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	200	$188.04	$37,608.00	Disclosure SEC source: 0001140361-18-032160 · doc1.xml · nonDerivative · entry 5 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,900 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document
July 09, 2018 Filed Jul 11, 2018 17:03 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	641	$187.37	$120,107.31	Disclosure SEC source: 0001140361-18-032160 · doc1.xml · nonDerivative · entry 4 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,100 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F5 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $186.89 to $187.86 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document
July 09, 2018 Filed Jul 11, 2018 17:03 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	200	$186.19	$37,238.00	Disclosure SEC source: 0001140361-18-032160 · doc1.xml · nonDerivative · entry 3 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,741 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F4 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $185.75 to $186.63 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document
July 09, 2018 Filed Jul 11, 2018 17:03 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	300	$185.34	$55,602.06	Disclosure SEC source: 0001140361-18-032160 · doc1.xml · nonDerivative · entry 2 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,941 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $184.73 to $185.57 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document
July 09, 2018 Filed Jul 11, 2018 17:03 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	Exercise / conversionCommon Stock	1,541	$3.65	$5,621.57	Disclosure SEC source: 0001140361-18-032160 · doc1.xml · nonDerivative · entry 1 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,241 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document
July 09, 2018 Filed Jan 17, 2019 08:08 UTC Amendment	Loxo Oncology, Inc. LOXO · Entity 160155	Exercise / conversionCommon Stock	1,541	$3.65	$5,621.57	Disclosure SEC source: 0001567619-19-001262 · doc1.xml · nonDerivative · entry 1 Van Naarden Jacob · CIK 0001661254 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,541 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · balance_after: This amended Form 4 is being filed solely to correct the reporting person's ending balance by subtracting the additional 1,700 shares of the Issuer's common stock (the "Additional Shares") that were added inadvertently to the total number of shares held directly by the reporting person. The Additional Shares were included in all the subsequent transactions in the Form 4 filed on July 11, 2018 and the five Forms 4 filed thereafter. As of January 17, 2019, the reporting person directly holds a total number of 19,000 shares of the Issuer's common stock. Read SEC document
June 20, 2018 Filed Jun 21, 2018 17:03 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	Exercise / conversionEmployee Stock Option (right to buy) · Derivative	1,541	$0.00 Strike: $3.65	$0.00	Disclosure SEC source: 0001140361-18-029487 · doc1.xml · derivative · entry 12 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,051 Underlying: Common Stock · 1,541 shares Expires 2024-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F7 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the shares subject to the option on May 12, 2015, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document
June 20, 2018 Filed Jun 21, 2018 17:03 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	Exercise / conversionEmployee Stock Option (right to buy) · Derivative	12,000	$0.00 Strike: $3.65	$0.00	Disclosure SEC source: 0001140361-18-029487 · doc1.xml · derivative · entry 11 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,592 Underlying: Common Stock · 12,000 shares Expires 2024-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the shares subject to the option on May 12, 2015, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document
June 20, 2018 Filed Jun 21, 2018 17:03 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	200	$180.90	$36,180.00	Disclosure SEC source: 0001140361-18-029487 · doc1.xml · nonDerivative · entry 9 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document
June 20, 2018 Filed Jun 21, 2018 17:03 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	200	$179.76	$35,951.00	Disclosure SEC source: 0001140361-18-029487 · doc1.xml · nonDerivative · entry 8 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,200 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F6 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $179.59 to $179.92 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document
June 20, 2018 Filed Jun 21, 2018 17:03 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	1,141	$179.00	$204,239.11	Disclosure SEC source: 0001140361-18-029487 · doc1.xml · nonDerivative · entry 7 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,400 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F5 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $178.57 to $179.38 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document
June 20, 2018 Filed Jun 21, 2018 17:03 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	Exercise / conversionCommon Stock	1,541	$3.65	$5,621.57	Disclosure SEC source: 0001140361-18-029487 · doc1.xml · nonDerivative · entry 6 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,541 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document
June 20, 2018 Filed Jun 21, 2018 17:03 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	Exercise / conversionCommon Stock	12,000	$3.65	$43,776.00	Disclosure SEC source: 0001140361-18-029487 · doc1.xml · nonDerivative · entry 5 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 19, 2018 Filed Jun 21, 2018 17:03 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	Exercise / conversionEmployee Stock Option (right to buy) · Derivative	1,541	$0.00 Strike: $3.65	$0.00	Disclosure SEC source: 0001140361-18-029487 · doc1.xml · derivative · entry 10 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,592 Underlying: Common Stock · 1,541 shares Expires 2024-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F7 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the shares subject to the option on May 12, 2015, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document
June 19, 2018 Filed Jun 21, 2018 17:03 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	100	$178.23	$17,823.00	Disclosure SEC source: 0001140361-18-029487 · doc1.xml · nonDerivative · entry 4 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document
June 19, 2018 Filed Jun 21, 2018 17:03 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	576	$177.47	$102,221.22	Disclosure SEC source: 0001140361-18-029487 · doc1.xml · nonDerivative · entry 3 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F4 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $177.08 to $178.02 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document
June 19, 2018 Filed Jun 21, 2018 17:03 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	865	$176.44	$152,621.72	Disclosure SEC source: 0001140361-18-029487 · doc1.xml · nonDerivative · entry 2 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 676 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $176.02 to $176.96 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document
June 19, 2018 Filed Jun 21, 2018 17:03 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	Exercise / conversionCommon Stock	1,541	$3.65	$5,621.57	Disclosure SEC source: 0001140361-18-029487 · doc1.xml · nonDerivative · entry 1 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,541 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document
May 15, 2018 Filed May 16, 2018 16:46 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	Exercise / conversionEmployee Stock Option (right to buy) · Derivative	1,541	$0.00 Strike: $3.65	$0.00	Disclosure SEC source: 0001140361-18-024225 · doc1.xml · derivative · entry 12 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,133 Underlying: Common Stock · 1,541 shares Expires 2024-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F8 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the shares subject to the option on May 12, 2015, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document
May 15, 2018 Filed May 16, 2018 16:46 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	200	$139.04	$27,808.00	Disclosure SEC source: 0001140361-18-024225 · doc1.xml · nonDerivative · entry 10 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document
May 15, 2018 Filed May 16, 2018 16:46 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	841	$138.35	$116,353.86	Disclosure SEC source: 0001140361-18-024225 · doc1.xml · nonDerivative · entry 9 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F7 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $137.77 to $138.65 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document
May 15, 2018 Filed May 16, 2018 16:46 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	300	$135.78	$40,734.00	Disclosure SEC source: 0001140361-18-024225 · doc1.xml · nonDerivative · entry 8 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,041 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F6 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $135.70 to $135.94 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document
May 15, 2018 Filed May 16, 2018 16:46 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	200	$133.35	$26,670.00	Disclosure SEC source: 0001140361-18-024225 · doc1.xml · nonDerivative · entry 7 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,341 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document
May 15, 2018 Filed May 16, 2018 16:46 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	Exercise / conversionCommon Stock	1,541	$3.65	$5,621.57	Disclosure SEC source: 0001140361-18-024225 · doc1.xml · nonDerivative · entry 6 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,541 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document
May 14, 2018 Filed May 16, 2018 16:46 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	Exercise / conversionEmployee Stock Option (right to buy) · Derivative	1,541	$0.00 Strike: $3.65	$0.00	Disclosure SEC source: 0001140361-18-024225 · doc1.xml · derivative · entry 11 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,674 Underlying: Common Stock · 1,541 shares Expires 2024-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F8 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the shares subject to the option on May 12, 2015, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document
May 14, 2018 Filed May 16, 2018 16:46 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	9	$139.45	$1,255.05	Disclosure SEC source: 0001140361-18-024225 · doc1.xml · nonDerivative · entry 5 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document
May 14, 2018 Filed May 16, 2018 16:46 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	691	$138.70	$95,842.18	Disclosure SEC source: 0001140361-18-024225 · doc1.xml · nonDerivative · entry 4 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F5 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $138.30 to $139.23 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document
May 14, 2018 Filed May 16, 2018 16:46 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	600	$137.50	$82,497.48	Disclosure SEC source: 0001140361-18-024225 · doc1.xml · nonDerivative · entry 3 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 700 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F4 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $136.99 to $137.87 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document
May 14, 2018 Filed May 16, 2018 16:46 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	241	$134.25	$32,354.15	Disclosure SEC source: 0001140361-18-024225 · doc1.xml · nonDerivative · entry 2 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,300 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $133.65 to $134.50 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.